Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity

Thrombosis and Haemostasis

Volumn 80, Issue 1, 1998, Pages 161-166

  Urano, Tetsumei ^a   Nagai, Nobuo ^a   Matsuura, Megumi ^a   Ihara, Hayato ^a   Takada, Yumiko ^a   Takada, Akikazu ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CALCIUM ION; FIBRIN; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VITRONECTIN;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CONTROLLED STUDY; DOSE RESPONSE; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL;

EID: 0031878755     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615156     Document Type: Article

References (38)

1. Loskutoff D J, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115.
2. Castellino FJ. Recent advances in the chemistry of the fibrinolytic system. Chem Rev 1981; 81: 431-46.
3. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost 1980; 43: 77-89.
4. Carrell RW, Evans DL, Stein PE. Mobile reactive centre of serpins and the control of thrombosis. Nature 1991; 353: 576-8.
5. Doolittle RF. Angiotensinogen is related to the antitrypsin-antithrombinovalbumin family. Science 1983; 222: 417-9.
6. Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655-709.
7. Huber R, Carrell RW. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 1989; 28: 8951-66.
8. Edelberg JM, Reilly CF, Pizzo SV. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a). J Biol Chem 1991; 266: 7488-93.
9. Urano T, Serizawa K, Takada Y, Ny T, Takada A. Heparin and heparan sulfate enhancement of the inhibitory activity of plasminogen activator inhibitor type 1 toward urokinase type plasminogen activator. Biochim Biophys Acta 1994; 1201: 217-22.
10. Ehrlich HJ, Gebbink RK, Keijer J, Linders M, Preissner KT, Pannekoek H. Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 1990; 265: 13029-35.
11. Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H. On the target specificity of plasminogen activator inhibitor-1: the role of heparin, vitronectin, and the reactive site. Blood 1991; 78: 1254-61.
12. Urano T, Ihara H, Takada Y, Nagai N, Takada A. The inhibition of human factor Xa by plasminogen activator inhibitor type 1 in the presence of calcium ion, and its enhancement by heparin and vitronectin. Biochim Biophys Acta 1996; 1298: 199-208.
13. Fa M, Karolin J, Aleshkov S, Strandberg L, Johansson LB, Ny T. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin. Biochemistry 1995; 34: 13833-40.
14. Ehrlich HJ, Gebbink RK, Preissner KT, Keijer J, Esmon NL, Mertens K, Pannekoek H. Thrombin neutralizes plasminogen activator inhibitor-1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol 1991; 115: 1773-81.
15. Urano T, Strandberg L, Johansson LB, Ny T. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate. Eur J Biochem 1992; 209: 985-92.
16. Lawrence D, Strandberg L, Grundström T, Ny T. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells. Eur J Biochem 1989; 186: 523-33.
17. Jameson GW, Roberts DV, Adams RW, Kyle WS, Elmore DT. Determination of the operational molarity of solutions of bovine alpha-chymotrypsin, trypsin, thrombin and factor Xa by spectrofluorimetric titration. Biochem J 1973; 131: 107-17.
18. Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-6.
19. Urano S, Metzger AR, Castellino FJ. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators. Proc Natl Acad Sci USA 1989; 86: 2568-71.
20. Carlson RH, Gamick RL, Jones AJ, Meunier AM. The determination of recombinant human tissue-type plasminogen activator activity by turbidimetry using a microcentrifugal analyzer. Anal Biochem 1988; 168: 428-35.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
22. Granelli PA, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-34.
23. Patston PA, Schapira M. Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin. Blood 1994; 84: 1164-72.
24. de Fouw Nj, van Hinsbergh VW, de Jong Yf, Haverkate F, Bertina RM. The interaction of activated protein C and thrombin with the plasminogen activator inhibitor released from human endothelial cells. Thromb Haemost 1987; 57: 176-82.
25. Madden RM, Levin EG, Marlar RA. Thrombin and the thrombin-thrombomodulin complex interaction with plasminogen activator inhibitor type-1. Blood Coagul Fibrinolysis 1991; 2: 471-6.
26. Naski MC, Lawrence DA, Mosher DF, Podor TJ, Ginsburg D. Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. Comparison of the effects of native and urea-treated forms of vitronectin. J Biol Chem 1993; 268: 12367-72.
27. Gebbink RK, Reynolds CH, Tollefsen DM, Mertens K, Pannekoek H. Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor-1. Biochemistry 1993; 32: 1675-80.
28. Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267: 24259-63.
29. Jackson CM. Factor X. Prog Hemost Thromb 1984; 7: 55-109.
30. Urano T, Sumiyoshi K, Pietraszek MH, Takada Y, Takada A. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 1991; 66: 474-8.
31. Urano T, Sakakibara K, Rydzewski A, Urano S, Takada Y, Takada A. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1. Thromb Haemost 1990; 63: 82-6.
32. Kojima Y, Urano T, Kojima K, Serizawa K, Takada Y, Takada A. The significant enhancement of fibrinolysis by calcium ion in a cell free system: the shortening of euglobulin clot lysis time by calcium ion. Thromb Haemost 1994; 72: 113-8.
33. Urano T, Chibber BA, Castellino FJ. The reciprocal effects of epsilon-aminohexanoic acid and chloride ion on the activation of human [Glul]plasminogen by human urokinase. Proc Natl Acad Sci USA 1987; 84:4031-4.
34. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-9.
35. Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-7.
36. Wu K, Urano T, Ihara H, Takada Y, Fujie M, Shikimori M, Hashimoto K, Takada A. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: The evaluation of its physiologic relevance in fibrinolysis. Blood 1995; 86, 1056-61.
37. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
38. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.